- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic kidney disease
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 387KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 54KB)
Dapagliflozin – March 2022
Dapagliflozin: Tablet 10 mg; Forxiga®
Last updated
1 July 2022